M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.

•M-M-R®II manufactured using either rHA or HSA was administered to healthy children 12–18 months and 3–4 years of age.•M-M-R®II manufactured using rHA was well-tolerated and was as immunogenic as M-M-R®II manufactured using HSA.•rHA is an acceptable replacement for HSA in the manufacture of M-M-R®II.